BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A

01 Mar 2021

Although small patient base offers modest revenue opportunity, the Nulibry approval enables BridgeBio to get commercial operations underway.

FDA approved background, 3D rendering, blue street sign — Nulibry for MoCD type A is BridgeBio's first approved drug

With a projected patient base of about 150 infants globally, BridgeBio Pharma, Inc. believes its newly approved Nulibry (fosdenopterin) will treat the smallest patient population for which a drug was solely created and approved. Nulibry, a recombinant form of cyclic pyranopterin monophosphate (cPMP), received US Food and Drug Administration (FDA) approval on 26 February to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.